Malignant brain tumors cause severe neurological deficits and are associated with poor prognosis and high recurrence rates despite significant advances in brain cancer therapy. Pet animals are frequently affected by similar brain cancer types as humans and have been recently recognized to be a powerful translational model for cancer therapy research. We strive to harness the neuroinfectious pathogens we study (canine distemper virus (CDV), Listeria monocytogenes ) to provide a microbial immunotherapy platform for brain cancer-immunotherapy in dogs and cats. This platform aims at fighting brain cancer at different levels by combining synergistic immunotherapeutic approaches: ( i ) the rearming of the antitumoral immune response by vaccination with Listeria monocytogenes delivering tumor-associated antigens (TAA) triggering the peripheral education and amplification of antitumoral CD8+ T-lymphocytes, (ii) the induction of immunogenic cell death (ICD) of cancer cells via engineered oncolytic CDV triggering tumor infiltration with CD8+ T-lymphocytes (iii) the direct delivery of immune checkpoint inhibitors into the tumor microenvironment via the oncolytic CDV vector.
Safety of a Novel Listeria monocytogenes -Based Vaccine Vector Expressing NcSAG1 ( Neospora caninum Surface Antigen Pownall WR, Imhof D, Trigo NF, Ganal-Vonarburg SC, Plattet P, Monney C, Forterre F, Hemphill A, Oevermann A. Front Cell Infect Microbiol . 2021 Aug 25;11:675219.
doi : 10.3389/fcimb.2021.675219. eCollection 2021.